Found: 1
Select item for more details and to access through your institution.
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 190, n. 2, p. 265, doi. 10.1007/s10549-021-06367-5
- By:
- Publication type:
- Article